PH-284 is under clinical development by VistaGen Therapeutics and currently in Phase II for Cachexia. According to GlobalData, Phase II drugs for Cachexia does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the PH-284 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PH-284 overview
PH284 is under development for wasting syndrome (cachexia ). PH284 belongs to a family of pharmaceutical compounds called pherines. These compounds are delivered through the nasal passages and in turn affect the hypothalamus and the limbic system. Pherines affect key areas of the brain. They initiate neural impulses that are transmitted by specific pathways that directly and rapidly affect brain function. As a consequence of binding to receptors, Pherines can influence the regulatory functions exerted by the hypothalamus and limbic system.
VistaGen Therapeutics overview
VistaGen Therapeutics (VistaGen) is a clinical-stage biopharmaceutical company that develops new-generation medicines for depression and neuropsychiatric disorders. The company’s pipeline product, AV-101, currently under Phase 2 clinical development, is an oral N-methyl-D-aspartate receptor glycine B intended to treat major depressive disorder. Its other pipeline products comprise PH94B treats social anxiety disorder and PH10 nasal spray treats major depressive disorder. The company offers its products in the form of sprays and oral administration. It partners with other healthcare industries for research and assessment of drug effects on cardiac risk. VistaGen is headquartered in South San Francisco, California, the US.
For a complete picture of PH-284’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
